Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz's Less Frequently Dosed Copaxone Generic Glatopa Hits Teva Two Months Early

Executive Summary

Teva said its 2018 revenue guidance reflected an April launch for the 40 mg dose of Glatopa, but Sandoz and partner Momenta announced FDA approval and the US launch of their less frequently administered Copaxone generic on Feb. 13.
Advertisement

Related Content

Teva Pushes CGRP Timeline Back To End Of 2018
How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch
How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch
Novartis Sale Of US Oral Generics Unit Seems Unlikely
Teva CEO Schultz Walks Smack Into A Rough Financial Situation
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Teva Catches A Break On Copaxone 40mg, But For How Long?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel